Spectrum Pharma drops after FDA response
NEW YORK |
NEW YORK (Reuters) - Spectrum Pharmaceuticals Inc (SPPI.O) shares tumbled 13 percent to $5.40 in premarket trade on Friday after the company received a complete response letter from the U.S. Food and Drug Administration regarding its supplemental new drug application for its advanced metastatic colorectal cancer treatment Fusilev.
The letter stated Fusilev did not demonstrate that the treatment is non-inferior to leucovorin.
(Reporting by Chuck Mikolajczak; editing by Jeffrey Benkoe)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters